About PerioTrap
PerioTrap Pharmaceuticals is developing an innovative anti-infective drug which will not only treat but also contribute to the eradication of periodontitis, an inflammatory gum disease caused by bacteria. To date, the most relevant therapy option is a painful procedure consisting of the manual removal of plaque within the dental pockets followed by cleansing using either antiseptic solutions or the administration of broad-spectrum antibiotics. PerioTrap’sapproach uses its newly developed, selective, small-molecule drugs to target only the disease-causing bacteria without affecting the commensal bacteria. Protecting the commensal bacteria should encourage a shift towards a natural microbiome, thus preventing the reoccurrence of the disease.
Latest News and Press Releases
3 Millionen Euro für neue Strategien im Kampf gegen die Volkskrankheit Parodontitis
5. April 2023
Halle (Saale), 05.04.2023. Im Kampf gegen Parodontitis erhält PerioTrap Unterstützung vom…
PerioTrap receives additional public grant to support non-clinical safety and efficacy of its microbiome shifting approach
23. Mai 2022
Halle (Saale), 23.05.2022. Antimicrobial resistance continues to be on the rise despite increased…
First Scientific Advisory Board Meeting endorses PerioTrap’s drug development progress
1. Dezember 2021
Halle (Saale), 23.11.2021. PerioTrap has received the official statement of its first Scientific…
PerioTrap Pharmaceuticals awarded 800.000,00 EUR public funding for developing new drugs and delivery systems for treating periodontitis
16. August 2021
Halle (Saale), 16.08.2021. Infectious diseases are often treated with broadband antibiotics that…
PerioTrap has published its efficient targeted periodontitis strategy that could minimize side effects and the overuse of broad-spectrum antibiotics.
1. Januar 2021
PerioTrap has published its efficient targeted periodontitis strategy that could minimize side…
PerioTrap Pharmaceuticals raises €3M seed round to develop selective anti-infectives to tackle periodontitis
21. Oktober 2020
Halle (Saale), 21.10.2020 – Although periodontitis is a widespread infectious disease affecting…
PerioTrap Pharmaceuticals ist Gesamtsieger des IQ Innovationspreis
25. Juni 2020
Für die Kombination aus einem neuartigen Medikament und Therapieansatz zur Bekämpfung von…
Antimicrobial activity study has been published
25. Juni 2020
After our mutual antimicrobial activity study has been published in April this year showing biofilm…